BioCentury
ARTICLE | Product Development

Getting hip in osteoporosis

Why romosozumab needs hip data to compete in osteoporosis

March 7, 2016 8:00 AM UTC

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower reduction in vertebral fracture rates than Radius Health Inc. has reported for abaloparatide-SC.

But doctors who spoke to BioCentury said if detailed data show evidence of efficacy on hip fractures, the mAb's monthly dosing schedule could level the playing field because of concerns that patients may not comply with abaloparatide-SC's once-daily regimen. ...